Webinar 29 October: Speed Without Compromise – From Complex Antibodies to Targeted Delivery

Sesselja Ómarsdóttir has spent her career moving between academia and industry, from lichen chemistry in an Icelandic lab to leading Genis today. She talks about mentorship, curiosity, and what it means to keep one foot in each world.


Stockholm-based Sobi has received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP), recommending an expanded indication for Tryngolza (olezarsen) to treat adults with severe hypertriglyceridemia (sHTG).

Finnish NADMED, a University of Helsinki spin-out, has partnered with US specialty laboratory Doctor’s Data to make its NAD biomarker measurement available to healthcare practitioners across the United States.

AstraZeneca has signed a drug discovery collaboration and licensing agreement with the AI therapeutics company insitro. The deal, worth up to approximately USD 1.5 billion, aims to identify new drug targets and therapies for metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies.

A new report from insurer Zurich finds that the life science sector’s greatest challenges arise only after discovery. The organizations best positioned to succeed will not necessarily be those with the most medical breakthroughs, but those that can scale up, finance, and deliver innovation reliably.

Modus Therapeutics has temporarily paused enrollment in Part 2 of its Phase IIa study of sevuparin in chronic kidney disease (CKD) with anemia after a serious adverse event in one patient. The company’s preliminary assessment is that the proof-of-concept readout will slip to the first quarter of 2027.

UK digital pathology provider Diagnexia has signed an agreement to use Swedish medical imaging IT company Sectra’s cloud-based Image Exchange Portal to receive, send and report on pathology cases from NHS organizations.